Allogene Therapeutics Other Stockholder Equity Over Time
| ALLO Stock | USD 2.21 0.10 4.74% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Allogene Therapeutics Performance and Allogene Therapeutics Correlation. Allogene |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Stockholder Equity Analysis
Compare Allogene Therapeutics and related stocks such as G1 Therapeutics, Heron Therapeuti, and Annexon Other Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HRTX | 28.1 M | 178.3 M | 236.8 M | 311.9 M | 382.8 M | 530.6 M | 564.3 M | 914 M | 1.3 B | 1.6 B | 1.6 B | 1.7 B | 1.8 B | 1.9 B | 2 B |
| ANNX | (26 K) | (26 K) | (26 K) | (26 K) | (26 K) | (26 K) | (26 K) | (26 K) | 1.3 M | 2.2 M | 154.4 M | 528.4 M | 669.8 M | 823 M | 864.2 M |
| SGMO | 759 K | 335.6 M | 342.8 M | 426.7 M | 538.4 M | 565.8 M | 582 M | 689.5 M | 929.2 M | 1.1 B | 1.3 B | 1.3 B | 1.5 B | 1.5 B | 1.6 B |
| BEAM | 28 K | 28 K | 28 K | 28 K | 28 K | 28 K | 28 K | 28 K | 7.9 M | 1.9 M | 642.6 M | 1.6 B | 1.8 B | 2.2 B | 2.3 B |
| SANA | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | (415.8 M) | 852.9 M | 1.5 B | 1.6 B | 1.6 B | 941.7 M |
| CRBU | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (33.9 M) | 485.7 M | 499.6 M | 667.6 M | 348 M |
| EDIT | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (20.6 M) | (15.9 M) | 320.1 M | 514 M | 652.5 M | 811.5 M | 1.1 B | 1.4 B | 1.4 B | 1.6 B | 1.7 B |
| RLAY | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | (529.1 M) | 1.2 B | 1.7 B | 2 B | 2.2 B | 1.2 B |
| IPSC | (32.9 M) | (32.9 M) | (32.9 M) | (32.9 M) | (32.9 M) | (32.9 M) | (32.9 M) | (32.9 M) | (32.9 M) | (32.9 M) | 185.9 M | 785 M | 824.3 M | 840.4 M | 572.6 M |
| BPMC | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 4.4 M | 102.1 M | 420.5 M | 979.8 M | 1 B | 1.4 B | 2.1 B | 2.3 B | 2.4 B | 2.5 B | 1.3 B |
| NTLA | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 89.3 M | 263.4 M | 421.7 M | 479 M | 570.5 M | 962.2 M | 1.7 B | 2.4 B | 2.7 B | 2.8 B |
| VERV | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (122.5 M) | 544.4 M | 895.8 M | 1.1 B | 1.2 B |
| ITOS | 11 K | 11 K | 11 K | 11 K | 11 K | 11 K | 11 K | 11 K | 11 K | 53.6 M | 396.4 M | 413.2 M | 435.7 M | 463.8 M | 323.2 M |
Allogene Therapeutics and related stocks such as G1 Therapeutics, Heron Therapeuti, and Annexon Other Stockholder Equity description
My Equities
My Current Equities and Potential Positions
| Allogene Therapeutics | ALLO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.21
Check out Allogene Therapeutics Performance and Allogene Therapeutics Correlation. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Allogene Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.